NZ585086A - Tetrahydroquinoline derivatives for treating post-traumatic stress disorders - Google Patents
Tetrahydroquinoline derivatives for treating post-traumatic stress disordersInfo
- Publication number
- NZ585086A NZ585086A NZ585086A NZ58508608A NZ585086A NZ 585086 A NZ585086 A NZ 585086A NZ 585086 A NZ585086 A NZ 585086A NZ 58508608 A NZ58508608 A NZ 58508608A NZ 585086 A NZ585086 A NZ 585086A
- Authority
- NZ
- New Zealand
- Prior art keywords
- formula
- phenyl
- pharmaceutically acceptable
- compound
- alkyl
- Prior art date
Links
- 208000028173 post-traumatic stress disease Diseases 0.000 title claims abstract description 18
- 125000000147 tetrahydroquinolinyl group Chemical class N1(CCCC2=CC=CC=C12)* 0.000 title abstract description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 44
- 150000003839 salts Chemical class 0.000 claims abstract description 37
- VEQOALNAAJBPNY-UHFFFAOYSA-N antipyrine Chemical compound CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 claims abstract description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 28
- -1 2-(4-trifluoromethyl-phenyl)-ethyl Chemical group 0.000 claims description 15
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- DKMACHNQISHMDN-RPLLCQBOSA-N Almorexant Chemical compound C([C@H]1C2=CC(OC)=C(OC)C=C2CCN1[C@@H](C(=O)NC)C=1C=CC=CC=1)CC1=CC=C(C(F)(F)F)C=C1 DKMACHNQISHMDN-RPLLCQBOSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 description 13
- 241000700159 Rattus Species 0.000 description 12
- 208000019901 Anxiety disease Diseases 0.000 description 11
- 230000036506 anxiety Effects 0.000 description 7
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 230000009257 reactivity Effects 0.000 description 6
- 229940123730 Orexin receptor antagonist Drugs 0.000 description 5
- 125000001072 heteroaryl group Chemical group 0.000 description 5
- 230000024188 startle response Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 229960003529 diazepam Drugs 0.000 description 4
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 230000002996 emotional effect Effects 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 208000011688 Generalised anxiety disease Diseases 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 2
- 230000000949 anxiolytic effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 208000029364 generalized anxiety disease Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108050000742 Orexin Receptor Proteins 0.000 description 1
- 102000008834 Orexin receptor Human genes 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Chemical group 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
- UCFFGYASXIPWPD-UHFFFAOYSA-N methyl hypochlorite Chemical compound COCl UCFFGYASXIPWPD-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000006606 n-butoxy group Chemical group 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229940000041 nervous system drug Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 125000005920 sec-butoxy group Chemical group 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB2007054130 | 2007-10-10 | ||
| PCT/IB2008/054138 WO2009047723A2 (en) | 2007-10-10 | 2008-10-09 | Tetrahydroquinoline derivatives for treating post-traumatic stress disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ585086A true NZ585086A (en) | 2012-03-30 |
Family
ID=40467356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ585086A NZ585086A (en) | 2007-10-10 | 2008-10-09 | Tetrahydroquinoline derivatives for treating post-traumatic stress disorders |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US9532985B2 (enExample) |
| EP (1) | EP2207550B1 (enExample) |
| JP (1) | JP5883222B2 (enExample) |
| KR (1) | KR101733247B1 (enExample) |
| CN (1) | CN101820878B (enExample) |
| AR (1) | AR068768A1 (enExample) |
| AU (1) | AU2008309194B2 (enExample) |
| BR (1) | BRPI0818617A2 (enExample) |
| CA (1) | CA2699504C (enExample) |
| CY (1) | CY1114799T1 (enExample) |
| DK (1) | DK2207550T3 (enExample) |
| EA (1) | EA017443B1 (enExample) |
| ES (1) | ES2444418T3 (enExample) |
| HR (1) | HRP20140214T1 (enExample) |
| IL (1) | IL204838A (enExample) |
| MA (1) | MA31800B1 (enExample) |
| MX (1) | MX2010003711A (enExample) |
| MY (1) | MY153044A (enExample) |
| NZ (1) | NZ585086A (enExample) |
| PE (1) | PE20091010A1 (enExample) |
| PL (1) | PL2207550T3 (enExample) |
| PT (1) | PT2207550E (enExample) |
| SI (1) | SI2207550T1 (enExample) |
| TW (1) | TWI428129B (enExample) |
| UA (1) | UA99150C2 (enExample) |
| WO (1) | WO2009047723A2 (enExample) |
| ZA (1) | ZA201003251B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2380391T3 (es) | 2006-12-22 | 2012-05-11 | Actelion Pharmaceuticals Ltd. | Derivados de 5,6,7,8-tetrahidro-imidazo[1,5-a]pirazina |
| US20110105514A1 (en) | 2008-06-25 | 2011-05-05 | Hamed Aissaoui | 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine compounds |
| EP2402322A1 (en) | 2010-07-02 | 2012-01-04 | Actelion Pharmaceuticals Ltd. | 1,2,3,4-tetrahydroisoquinoline derivative and its use as orexin receptor antagonist |
| TW201209037A (en) | 2010-08-24 | 2012-03-01 | Actelion Pharmaceuticals Ltd | Proline sulfonamide derivatives as orexin receptor antagonists |
| SI2626350T1 (sl) | 2010-09-22 | 2015-09-30 | Eisai R&D Management Co., Ltd. | Spojina ciklopropana |
| WO2012063207A1 (en) | 2010-11-10 | 2012-05-18 | Actelion Pharmaceuticals Ltd | Lactam derivatives useful as orexin receptor antagonists |
| WO2012085852A1 (en) | 2010-12-22 | 2012-06-28 | Actelion Pharmaceuticals Ltd | 3,8-diaza-bicyclo[4.2.0]oct-8-yl amides |
| WO2012110986A1 (en) | 2011-02-18 | 2012-08-23 | Actelion Pharmaceuticals Ltd | Novel pyrazole and imidazole derivatives useful as orexin antagonists |
| WO2012114252A1 (en) | 2011-02-21 | 2012-08-30 | Actelion Pharmaceuticals Ltd | Novel indole and pyrrolopyridine amides |
| WO2013050938A1 (en) | 2011-10-04 | 2013-04-11 | Actelion Pharmaceuticals Ltd | 3,7-diazabicyclo[3.3.1]nonane and 9-oxa-3,7-diazabicyclo[3.3.1]nonane derivatives |
| DK2776430T3 (en) | 2011-11-08 | 2016-05-09 | Actelion Pharmaceuticals Ltd | 2- (1,2,3-triazol-2-yl) benzamide and 3- (1,2,3-triazol-2-yl) PICOLINAMIDDERIVATER AS orexin receptor antagonists |
| TWI570120B (zh) | 2012-06-04 | 2017-02-11 | 艾克泰聯製藥有限公司 | 苯并咪唑脯胺酸衍生物 |
| AU2013328301A1 (en) | 2012-10-10 | 2015-05-28 | Actelion Pharmaceuticals Ltd | Orexin receptor antagonists which are [ortho bi (hetero-)aryl]-[2-(meta bi (hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives |
| CN105051040A (zh) | 2013-03-12 | 2015-11-11 | 埃科特莱茵药品有限公司 | 作为食欲素受体拮抗剂的氮杂环丁烷酰胺衍生物 |
| JP6496733B2 (ja) | 2013-12-03 | 2019-04-03 | イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | （ｓ）−（２−（６−クロロ−７−メチル−１ｈ−ベンゾ［ｄ］イミダゾール−２−イル）−２−メチルピロリジン−１−イル）（５−メトキシ−２−（２ｈ−１，２，３−トリアゾール−２−イル）フェニル）メタノンの結晶形及びオレキシン受容体アンタゴニストとしてのその使用 |
| UA119151C2 (uk) | 2013-12-03 | 2019-05-10 | Ідорсія Фармасьютікалз Лтд | КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА |
| KR102330133B1 (ko) | 2013-12-04 | 2021-11-23 | 이도르시아 파마슈티컬스 리미티드 | 벤즈이미다졸-프롤린 유도체의 용도 |
| SG10202007759RA (en) | 2014-10-23 | 2020-09-29 | Eisai R&D Man Co Ltd | Compositions and methods for treating insomnia |
| CN115710250A (zh) * | 2017-08-01 | 2023-02-24 | 博健制药有限责任公司 | 一种食欲素受体拮抗剂的晶型及其制备方法和用途 |
| WO2020007964A1 (en) | 2018-07-05 | 2020-01-09 | Idorsia Pharmaceuticals Ltd | 2-(2-azabicyclo[3.1.0]hexan-1-yl)-1h-benzimidazole derivatives |
| WO2020007977A1 (en) | 2018-07-06 | 2020-01-09 | Idorsia Pharmaceuticals Ltd | 7-trifluoromethyl-[1,4]diazepan derivatives |
| WO2020099511A1 (en) | 2018-11-14 | 2020-05-22 | Idorsia Pharmaceuticals Ltd | Benzimidazole-2-methyl-morpholine derivatives |
| TW202400149A (zh) | 2022-05-13 | 2024-01-01 | 瑞士商愛杜西亞製藥有限公司 | 經噻唑并芳基-甲基取代之環狀肼-n-甲醯胺衍生物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6011301A (en) * | 2000-03-14 | 2001-09-24 | Actelion Pharmaceuticals Ltd | 1,2,3,4-tetrahydroisoquinoline derivatives |
| AU2004224156B2 (en) * | 2003-03-26 | 2010-08-12 | Actelion Pharmaceuticals Ltd. | Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists |
| JP4094050B2 (ja) * | 2004-03-01 | 2008-06-04 | アクテリオン ファーマシューティカルズ リミテッド | 置換１，２，３，４−テトラヒドロイソキノリン誘導体 |
| US7501395B2 (en) * | 2005-04-25 | 2009-03-10 | Eisai R & D Management Co., Ltd. | Method of screening for antianxiety drugs |
| EP1998774A1 (en) | 2006-03-15 | 2008-12-10 | Actelion Pharmaceuticals Ltd. | Tetrahydroisoquinoline derivatives to enhance memory function |
| EP2402322A1 (en) | 2010-07-02 | 2012-01-04 | Actelion Pharmaceuticals Ltd. | 1,2,3,4-tetrahydroisoquinoline derivative and its use as orexin receptor antagonist |
-
2008
- 2008-10-07 PE PE2008001739A patent/PE20091010A1/es not_active Application Discontinuation
- 2008-10-09 DK DK08807937.1T patent/DK2207550T3/da active
- 2008-10-09 WO PCT/IB2008/054138 patent/WO2009047723A2/en not_active Ceased
- 2008-10-09 SI SI200831152T patent/SI2207550T1/sl unknown
- 2008-10-09 AU AU2008309194A patent/AU2008309194B2/en not_active Ceased
- 2008-10-09 KR KR1020107010186A patent/KR101733247B1/ko not_active Expired - Fee Related
- 2008-10-09 EP EP08807937.1A patent/EP2207550B1/en active Active
- 2008-10-09 US US12/681,802 patent/US9532985B2/en not_active Expired - Fee Related
- 2008-10-09 ES ES08807937.1T patent/ES2444418T3/es active Active
- 2008-10-09 CN CN2008801113334A patent/CN101820878B/zh not_active Expired - Fee Related
- 2008-10-09 JP JP2010528515A patent/JP5883222B2/ja not_active Expired - Fee Related
- 2008-10-09 EA EA201000557A patent/EA017443B1/ru not_active IP Right Cessation
- 2008-10-09 HR HRP20140214AT patent/HRP20140214T1/hr unknown
- 2008-10-09 BR BRPI0818617-0A patent/BRPI0818617A2/pt not_active Application Discontinuation
- 2008-10-09 PT PT88079371T patent/PT2207550E/pt unknown
- 2008-10-09 UA UAA201005122A patent/UA99150C2/ru unknown
- 2008-10-09 TW TW097139093A patent/TWI428129B/zh not_active IP Right Cessation
- 2008-10-09 CA CA2699504A patent/CA2699504C/en active Active
- 2008-10-09 AR ARP080104422A patent/AR068768A1/es unknown
- 2008-10-09 MY MYPI2010001561A patent/MY153044A/en unknown
- 2008-10-09 MX MX2010003711A patent/MX2010003711A/es active IP Right Grant
- 2008-10-09 PL PL08807937T patent/PL2207550T3/pl unknown
- 2008-10-09 NZ NZ585086A patent/NZ585086A/en not_active IP Right Cessation
-
2010
- 2010-04-06 IL IL204838A patent/IL204838A/en active IP Right Grant
- 2010-04-30 MA MA32806A patent/MA31800B1/fr unknown
- 2010-05-07 ZA ZA2010/03251A patent/ZA201003251B/en unknown
-
2014
- 2014-02-04 CY CY20141100085T patent/CY1114799T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2699504C (en) | Tetrahydroquinoline derivatives for treating post-traumatic stress disorders | |
| JP5582535B2 (ja) | 点眼投与による神経疾患または精神神経疾患の治療または予防 | |
| US20100249164A1 (en) | Modulation of sleep with nr2b receptor antagonists | |
| WO2015106268A1 (en) | USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | |
| EP2156833A1 (en) | Prophylactic or therapeutic agent for posterior ocular disease comprising non-ergot selective d2 receptor agonist as active ingredient | |
| TWI243678B (en) | A pharmaceutical composition for the treatment and/or prophylaxis of conditions characterized by altered bowel function and/or visceral pain in human or non-human mammals | |
| MXPA00013033A (es) | Sulfonamidas que contienen isoesteres n-heterociclicos para las enfermedades de la vision y la memoria. | |
| US20120035207A1 (en) | Use of GABAA Receptor Agonists for the Treatment of Hearing, Vestibular and Attention Disorders, Intention Tremor and Restless Leg Syndrome | |
| UA123352C2 (uk) | Застосування похідних піридазину для попередження або лікування атаксичного синдрому | |
| JP2008542417A (ja) | 進行性ミオクローヌスてんかんに特徴付けられる疾患の治療用ブリバラセタムの使用 | |
| IL262920A (en) | A triangular combination of pure 5 – ht6 receptor antagonists, acetylcholinesterase inhibitors and nmda receptor agonists | |
| IL262816A (en) | Combination of pure 5 – ht6 receptor antagonists with nmda receptor agonist | |
| HK1145440B (en) | Tetrahydroquinoline derivatives for treating post-traumatic stress disorders | |
| JP2007519733A (ja) | アンパカインにより誘導されるシナプス応答促通のコリンエステラーゼ阻害剤による増強方法 | |
| KR980008226A (ko) | 시각기능장애의 예방 및 치료제 | |
| Sévoz-Couche et al. | Antinociceptive effect of cardiopulmonary chemoreceptor and baroreceptor reflex activation in the rat | |
| MXPA00013031A (es) | Ureas y carbamatos de acidos carboxilicos n-heterociclicos e isoesteres, para las enfermedades de la vision y la memoria. | |
| US20260076935A1 (en) | Prevention and treatment of conditions using ethyl pyruvate | |
| Alkozi et al. | Improving melatonin delivery within the eye | |
| JP2002522482A (ja) | 視力及び記憶障害に対する多様な異種原子を有するヘテロサイクリック環化合物のカルボン酸及び同配体 | |
| WO2014172453A2 (en) | Novel compositions useful in treating brain-related diseases or disorders and methods using same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 OCT 2016 BY DENNEMEYER + CO Effective date: 20150917 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 OCT 2017 BY DENNEMEYER + CO Effective date: 20160921 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 OCT 2018 BY DENNEMEYER + CO Effective date: 20170926 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 OCT 2019 BY DENNEMEYER + CO Effective date: 20180928 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 OCT 2020 BY DENNEMEYER + CO. Effective date: 20190920 |
|
| ASS | Change of ownership |
Owner name: IDORSIA PHARMACEUTICALS LTD, CH Effective date: 20200602 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 OCT 2021 BY DENNEMEYER + CO. S.A.R.L. Effective date: 20200928 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 OCT 2022 BY DENNEMEYER + CO. Effective date: 20210928 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 OCT 2023 BY DENNEMEYER + CO. S.A.R.L. Effective date: 20220926 |
|
| LAPS | Patent lapsed |